Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients

Recent Developments in Application of Multiparametric Flow Cytometry in CAR-T Immunotherapy

“…Although some studies have shown that the efficacy of CAR-T is highly dependent on the density of target antigen expression [36,37], and clinical trials has found that high tumor burden is a high-risk factor to relapse [40,41], more detailed data remains unclear. For example, the percentage and numbers of antigen expressed on tumor cells and the expression intensity that can activate CAR-T to obtain the best response rate and longest survival rate; the suitable target antigen expression in tumor cells that allows the patient to be enrolled in the CAR-T study; the corresponding relations between absolute counts of target positive tumor cells or antigens on total tumor cells and dose of CAR-T needed for treatment [63,64], etc. On the other side, the efficacy, stability, and difference of CAR detection antibody, qualitative and quantitative heterogeneity of antigen expression on tumor cells in the same disease, differences in antigen expression intensity caused by different fluorescence, and the influence factors in the process of antibody staining, can lead to significant intra-lab and inter-lab differences.…”